[8-K] GeneDx Holdings Corp. Reports Material Event
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
GeneDx Holdings Corp. furnished an 8-K announcing it issued a press release and will hold a conference call to discuss financial results for the quarter ended September 30, 2025.
The company attached its Press Release and an Earnings Presentation as Exhibits 99.1 and 99.2. The materials are furnished under Item 2.02 and are not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference, except as specifically stated.
GeneDx Holdings Corp. ha fornito un 8-K annunciando di aver emesso un comunicato stampa e che terrà una conferenza telefonica per discutere i risultati finanziari del trimestre terminato il 30 settembre 2025. L'azienda ha allegato il Press Release e una Earnings Presentation come Allegati 99.1 e 99.2. I materiali sono forniti ai sensi della voce Item 2.02 e non sono considerati depositati ai sensi della Sezione 18 dell'Exchange Act né incorporati per riferimento, salvo quanto specificamente indicato.
GeneDx Holdings Corp. presentó un 8-K anunciando que emitió un comunicado de prensa y celebrará una llamada de conferencia para discutir los resultados financieros del trimestre terminado el 30 de septiembre de 2025. La empresa adjuntó su Press Release y una Earnings Presentation como Exhibits 99.1 y 99.2. Los materiales se proporcionan bajo el Ítem 2.02 y no se consideran presentados conforme a la Sección 18 de la Exchange Act ni incorporados por referencia, salvo lo expresamente indicado.
GeneDx Holdings Corp.은 8-K를 제출했고 보도자료를 발행했으며 2025년 9월 30일에 종료된 분기의 재무 결과를 논의하기 위한 컨퍼런스 콜을 개최할 것임을 발표했습니다. 회사는 Press Release와 Earnings Presentation를 Exhibits 99.1 및 99.2로 첨부했습니다. 자료는 항목 2.02에 따라 제공되며 Exchange Act의 섹션 18에 따라 “filed”로 간주되지 않으며, 구체적으로 명시된 경우를 제외하고 참조에 포함되지 않습니다.
GeneDx Holdings Corp. a fourni un 8-K annonçant qu'il a publié un communiqué de presse et qu'il tiendra une conférence téléphonique pour discuter des résultats financiers du trimestre terminé le 30 septembre 2025. La société a joint son Press Release et une Earnings Presentation en tant qu'Exhibits 99.1 et 99.2. Les documents sont fournis en vertu de l'Article 2.02 et ne sont pas considérés comme « déposés » en vertu de la Section 18 de la Exchange Act ni incorporés par référence, sauf indication contraire.
GeneDx Holdings Corp. hat eine 8-K vorgelegt und mitgeteilt, dass ein Pressemitteilung veröffentlicht wurde und dass eine Telefonkonferenz abgehalten wird, um die finanziellen Ergebnisse für das Quartal zum 30. September 2025 zu besprechen. Das Unternehmen hat seine Press Release und eine Earnings Presentation als Exhibits 99.1 und 99.2 beigefügt. Die Materialien werden gemäß Abschnitt 2.02 bereitgestellt und gelten nicht als "eingereicht" gemäß Abschnitt 18 des Exchange Act oder durch Verweis aufgenommen, außer wie ausdrücklich angegeben.
أصدرت GeneDx Holdings Corp. نموذج 8-K معلنة أنها أصدرت بياناً صحفياً وستعقد مكالمة عامة لمناقشة النتائج المالية للربع المنتهي في 30 سبتمبر 2025. أرفقت الشركة Press Release وEarnings Presentation كمعروضين 99.1 و 99.2. تُقدَّم المواد بموجب البند 2.02 وليست مُعتَبَرَة "مقدمة" بموجب القسم 18 من قانون التبادل، ولا مُضمَّنة بالمرجع، باستثناء ما يُذكر بشكل خاص.
Positive
- None.
Negative
- None.
GeneDx Holdings Corp. ha fornito un 8-K annunciando di aver emesso un comunicato stampa e che terrà una conferenza telefonica per discutere i risultati finanziari del trimestre terminato il 30 settembre 2025. L'azienda ha allegato il Press Release e una Earnings Presentation come Allegati 99.1 e 99.2. I materiali sono forniti ai sensi della voce Item 2.02 e non sono considerati depositati ai sensi della Sezione 18 dell'Exchange Act né incorporati per riferimento, salvo quanto specificamente indicato.
GeneDx Holdings Corp. presentó un 8-K anunciando que emitió un comunicado de prensa y celebrará una llamada de conferencia para discutir los resultados financieros del trimestre terminado el 30 de septiembre de 2025. La empresa adjuntó su Press Release y una Earnings Presentation como Exhibits 99.1 y 99.2. Los materiales se proporcionan bajo el Ítem 2.02 y no se consideran presentados conforme a la Sección 18 de la Exchange Act ni incorporados por referencia, salvo lo expresamente indicado.
GeneDx Holdings Corp.은 8-K를 제출했고 보도자료를 발행했으며 2025년 9월 30일에 종료된 분기의 재무 결과를 논의하기 위한 컨퍼런스 콜을 개최할 것임을 발표했습니다. 회사는 Press Release와 Earnings Presentation를 Exhibits 99.1 및 99.2로 첨부했습니다. 자료는 항목 2.02에 따라 제공되며 Exchange Act의 섹션 18에 따라 “filed”로 간주되지 않으며, 구체적으로 명시된 경우를 제외하고 참조에 포함되지 않습니다.
GeneDx Holdings Corp. a fourni un 8-K annonçant qu'il a publié un communiqué de presse et qu'il tiendra une conférence téléphonique pour discuter des résultats financiers du trimestre terminé le 30 septembre 2025. La société a joint son Press Release et une Earnings Presentation en tant qu'Exhibits 99.1 et 99.2. Les documents sont fournis en vertu de l'Article 2.02 et ne sont pas considérés comme « déposés » en vertu de la Section 18 de la Exchange Act ni incorporés par référence, sauf indication contraire.
GeneDx Holdings Corp. hat eine 8-K vorgelegt und mitgeteilt, dass ein Pressemitteilung veröffentlicht wurde und dass eine Telefonkonferenz abgehalten wird, um die finanziellen Ergebnisse für das Quartal zum 30. September 2025 zu besprechen. Das Unternehmen hat seine Press Release und eine Earnings Presentation als Exhibits 99.1 und 99.2 beigefügt. Die Materialien werden gemäß Abschnitt 2.02 bereitgestellt und gelten nicht als "eingereicht" gemäß Abschnitt 18 des Exchange Act oder durch Verweis aufgenommen, außer wie ausdrücklich angegeben.
أصدرت GeneDx Holdings Corp. نموذج 8-K معلنة أنها أصدرت بياناً صحفياً وستعقد مكالمة عامة لمناقشة النتائج المالية للربع المنتهي في 30 سبتمبر 2025. أرفقت الشركة Press Release وEarnings Presentation كمعروضين 99.1 و 99.2. تُقدَّم المواد بموجب البند 2.02 وليست مُعتَبَرَة "مقدمة" بموجب القسم 18 من قانون التبادل، ولا مُضمَّنة بالمرجع، باستثناء ما يُذكر بشكل خاص.
GeneDx Holdings Corp. 已提交一份8-K，宣布已发布新闻稿并将举行电话会议，讨论截至2025年9月30日季度的财务业绩。该公司将其 Press Release 和 Earnings Presentation 作为 Exhibits 99.1 和 99.2 附上。材料是在 2.02 项下提供的，且不被视为根据证券交易法第18条“备案”或通过引用纳入，除非另有具体说明。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 28, 2025
Commission file number 001-39482
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||
| (Address of Principal Executive Offices) (Zip Code) | |||||
Registrant's telephone number, including area code: (888 ) 729-1206
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 28, 2025 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended September 30, 2025. Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No | Description | ||||
99.1 | Press Release, dated October 28, 2025, regarding the registrant’s results for the quarter ended September 30, 2025 | ||||
99.2 | Earnings Presentation, dated October 28, 2025 | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GENEDX HOLDINGS CORP. | |||||||||||
| Date: | By: | /s/ Katherine Stueland | |||||||||
| Name: | Katherine Stueland | ||||||||||
| Title: | Chief Executive Officer | ||||||||||
GeneDx Holdings Corp
NASDAQ:WGS
WGS Rankings
WGS Latest News
WGS Latest SEC Filings
Sep 30, 2025
[144] GeneDx Holdings Corp. SEC Filing
WGS Stock Data
3.75B
25.18M
12.35%
110.61%
12.65%
Diagnostics & Research
Services-health Services
United States
STAMFORD